Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results
Non-regulated information
Eight Idylla™ Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US
Non-regulated information
Studies on Idylla™ MSI and RAS liquid biopsy tests to be presented at ESMO congress
Non-regulated information
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
Non-regulated information
Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)
Non-regulated information
Biocartis launches innovative Idylla™ MSI Assay
Non-regulated information
Study Reviewing 2,500 Performed Idylla™ Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Non-regulated information
Study Demonstrates Ability of Idylla™ EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
Non-regulated information
Two Performance Studies on Idylla™ MSI Biomarkers Selected for Publication at ASCO Conference
Non-regulated information
Biocartis Abstract on Performance Idylla™ ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting